Orphan Therapies

Orphan Therapies is a non-profit biopharmaceutical company and a wholly owned subsidiary of the Orphan Therapeutics Accelerator (OTXL). The company specializes in providing commercial access to treatments for ultra-rare diseases that are often overlooked by traditional for-profit biotech firms due to high development costs and extremely small patient populations. By utilizing a streamlined, non-profit model, Orphan Therapies aims to create sustainable and scalable pathways for shelved or niche clinical-stage treatments. Its lead initiative involves a partnership with Fondazione Telethon to facilitate the U.S. commercial launch of an FDA-approved ex vivo gene therapy for Wiskott-Aldrich syndrome. The organization operates with a mission-driven focus, reinvesting net proceeds to support the ongoing development of additional rare disease therapies.